全反式维甲酸联合替莫唑胺对U251细胞的作用  

Effect of all-trans retinoic acid combined with temozolomide on U251 glioma cells

作　　者：吴长松[1] 徐国政[2] 张新元[2] 吴越[1] 刁波[2] 卢文婕[2] 

机构地区：[1]南方医科大学,广州510515 [2]广州军区武汉总医院神经外科

出　　处：《中华实验外科杂志》2013年第9期1813-1815,共3页Chinese Journal of Experimental Surgery

摘　　要：目的 观察全反式维甲酸（ATRA）与替莫唑胺（TMZ）联合应用对人脑胶质瘤细胞株U251的作用.方法 用ATRA和TMZ单独及联合作用于U251细胞株,噻唑蓝（MTT）比色法测各组细胞的生长抑制率,流式细胞术检测细胞凋亡率,Western blot检测B细胞淋巴瘤/白血病-2（bcl-2）相关X蛋白（bax）/bcl-2、半胱氨酰天冬氨酸特异性蛋白酶（Caspase）-3、Caspase-8、Caspase-9等蛋白表达.结果 ATRA组、TMZ组和联合用药组细胞生长抑制率分别为（43.64 ±5.09）％、（35.77±5.39）％、（56.84±4.18）％；细胞凋亡率分别为（24.93±4.58）％、（21.36±3.76）％、（41.66±5.02）％.与对照组比较,bcl-2在3组中表达均下调,而bax、Caspase-3、Caspase-8、Caspase-9表达均上调,联合用药组更明显.结论 ATRA和TMZ两药均可抑制U251细胞株生长,促进细胞凋亡,并具有协同作用；其机制可能与下调bcl-2、上调bax/bcl-2、Caspase-3、Caspase-8、Caspase-9等蛋白表达有关.Objective To investigate the effect of combined treatment of all-trans retinoic acid （ATRA） and temozolomide （TMZ） on U251 glioma cells.Methods U251 glioma cells were treated with ATRA,TMZ,or ATRA combined with TMZ.The growth inhibition rate of each group was tested by using methyl thiazol tetrazolium （MTF） assay,and the apoptosis rate was analyzed by using flow cytometry.The protein expression of bax/bcl-2,Caspase-3,Caspase-8 and Caspase-9 was detected by using Western blotting.Results The growth inhibition rate of U251 glioma cells in ATRA group,TMZ group and combination group was （43.64 ± 5.09） ％,（35.77 ± 5.39） ％ and （56.84 ± 4.18） ％,and the apoptosis rate was （24.93.± 4.58） ％,（21.36 ± 3.76） ％ and （41.66 ± 5.02） ％,respectively.In ATRA group,TMZ group and combination group,the expression of bcl-2 was lower,but that of bax,Caspase-3,Caspase-8 and Caspase-9 was higher than in control group.These changes were more obvious in the combination group.Conclusion Both ATRA and TMZ can inhibit the growth of U251 cells and promote apoptosis,and exert the synergetic effect,which may be related to the down-regulation of the expression of bcl-2 and upregulation of bax/bcl-2,Caspase-3,Caspase-8 and Caspase-9 in U251 cells.

关 键 词：全反式维甲酸 替莫唑胺 脑胶质瘤 脱噬作用 

分 类 号：R739.41[医药卫生—肿瘤]